O'Brien Patrick's Form 4 filing
Arrowhead Pharmaceuticals, Inc. (ARWR) · filed Jan 5, 2024
- Accession no.
- 0001628280-24-000744
- Filed
- Jan 5, 2024
- Trade date
- Jan 3-5, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 9 non-derivative transactions and 0 derivative transactions. Open-market sales total $1.14M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| O'Brien PatrickCIK 0001627183 | Officer (COO and General Counsel) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 3, 2024 | Common Stock | SSaleDisposed | −3,849 | $31.83 | −$122,513.67 | 408,726 | Direct | |
| Jan 3, 2024 | Common Stock | SSaleDisposed | −2,800 | $32.52 | −$91,056 | 405,926 | Direct | |
| Jan 3, 2024 | Common Stock | SSaleDisposed | −400 | $33.41 | −$13,364 | 405,526 | Direct | |
| Jan 3, 2024 | Common Stock | SSaleDisposed | −1,700 | $32.65 | −$55,505 | 403,826 | Direct | |
| Jan 4, 2024 | Common Stock | SSaleDisposed | −1,600 | $32.63 | −$52,208 | 402,226 | Direct | |
| Jan 4, 2024 | Common Stock | AGrant or awardAcquired | +85,000 | $0.00 | $0 | 487,226 | Direct | |
| Jan 5, 2024 | Common Stock | SSaleDisposed | −1,900 | $33.99 | −$64,581 | 485,326 | Direct | |
| Jan 5, 2024 | Common Stock | SSaleDisposed | −8,200 | $34.99 | −$286,918 | 477,126 | Direct | |
| Jan 5, 2024 | Common Stock | SSaleDisposed | −12,741 | $35.65 | −$454,216.65 | 464,385 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.